agonists into the same sites in pontomedullary motor "inhibitory" areas of decerebrate animals produced opposite effects on muscle tone. Microinjection of non-NMDA agonists into peri-locus coeruleus alpha (peri-LCa) and nucleus magnocellularis (NMC) suppressed muscle tone, while injection of NMDA agonists at the same sites increased muscle tone and produced locomotion.
The latency, duration, and magnitude of muscle tone change after both NMDA and non-NMDA agonist injections were dose dependent.
Increased muscle tone and locomotor effects were blocked by NMDA antagonists, and muscle tone suppression effects were blocked by non-NMDA antagonists.
We conclude that pontomedullary non-NMDA receptors mediate muscle tone suppression, and that NMDA receptors mediate locomotion and muscle tone facilitation. Activation of both NMDA and non-NMDA pontomedullary receptors by glutamate release in REM sleep can explain the combination of motor activation and loss of muscle tone that characterizes this state. In the waking animal, the co-localization of these mechanisms may facilitate the coordination of locomotion with postural adjustments.
REM sleep is characterized by a complete suppression of muscle tone, combined with a seemingly "paradoxical" central motor activation. Muscle tone suppression requires the integrity of the dorsolateral pons (Jouvet and Delorme, 1965; Hendricks et al., 1982; Chase, 1983; Amini-Sereshki and Morrison, 1986 ) and medial medulla (Schenkel and Siegel, 1989) . Damage to these regions produces REM sleep without atonia, during which elaborate motor activities are expressed in a state with all of the other characteristics of REM sleep. lnfusion of cholinergic agonists into the dorsolateral pons induces atonia and other signs of REM sleep (George et al., 1964; van Dongen et al., 1978; Baghdoyan et al., 1984; Katayama et al., 1984; Shiromani et al., 1986) .
Electrical stimulation of the nucleus magnocellularis (NMC) and paramedianus of the medial medulla and of the dorsolateral pontine tegumentum produces suppression of muscle tone (Lai et al., 1987; Lai and Siegel, 1990a) . Recently, we reported that repetitive electrical stimulation of these sites transformed the Feb. 11, 1991; revised Apr. 4, 1991; accepted Apr. 25, 1991 (Lai and Siegel, 199Oa) . The atonia response in the per&locus coeruleus region and in the NMC of the medial medulla is not mediated by fibers of passage since it can be induced by activation of non-NMDA glutamate receptors (Lai and Siegel, 1988) . In the present study, we sought to determine if the locomotor response could be triggered by chemical stimulation of the same sites and to identify the receptor responsible for this effect.
Received

Materials and Methods
Experiments were performed on 17 unanesthetized, pre-collicular-postmammillary decerebrate cats of either sex, weighing 2.24.5 kg. Surgical urocedures were described ureviouslv (Lai and Siegel. 1990b) . Core iemperature was maintainedat 38 t i0c by a therm&e&lated heating pad. Blood pressure was monitored, and mean arterial blood pressure remained over 80 mm Hg in all preparations. Electromyograms were recorded from occipitoscapularis, splenius, and biventer cervices of the neck and triceps brachii muscles of the forelimb. The areas producing bilateral inhibition of muscle tone were identified by electrical stimulation (500 msec trains with 100 Hz, 0.2 msec, 20-70 PA rectangular cathodal pulses) through a stainless-steel monopolar microelectrode with tip size of 0.0 1 inch (model 57 10, A-M Systems, Inc.). The region from Pl to P4, 14 mm from the midline and O-6.0 mm dorsoventrally in the pons, and from P8 to Pl 1, 1 mm from the midline and from -7.0 to -9.0 dorsoventrally in the medulla (Berman, 1968) was explored in 0.5 mm increments. Once the inhibitory area was identified, 0.5 ~1 of each of several glutamate agonists at varying concentrations was microinjected over a 2 min period through a stereotaxically positioned. 1 ~1 Hamilton microsyringe (7001, 26S-gauge) . Antagonist experiments were performed by injecting antagonist followed by agonist after a 5 min interval. Agonist was microinjected again after 2 or 10 hr to confirm the baseline response. Recovery of agonist effects occurred in every case. The interval between two experiments at the same site was a minimum of 2 hr. In eight sites, only one non-NMDA agonist was injected. In 15 sites, two or-three non-NMDA agonists were injected. In eight sites, onlv NMDA agonists were iniected. In five sites. both NMDA and non-NMDA agonists were injected. At two of these sites the NMDA agonists were injected first, while in three, non-NMDA agonists were injected first. Duration of the inhibitory effects was calculated from the point of suppression of muscle tone below 50% of the preinjection level and recovery, the point at which tone returned to above 50% of baseline levels. Duration of excitatory effects was calculated from the time at which muscle tone increased 50% above preinjection level or at which rhythmic movement began.
kll chemicals except 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and 6.7-dinitroauinoxaline-2.3-dione (DNOX) were dissolved in Ringer's saline sol&on, pH adjuited to 7.>2-7.4: dNQX and DNQX were dissolved in 45% aqueous 2-hydroxypropyl-/3-cyclodextrin and then diluted with Ringer's saline. The injection sites were verified by electrolytic iron deposits revealed by the ferrocyanide reaction.
Results
Electrical stimulation-induced muscle tone suppression could be found from P2 to P4, 2-3.5 mm from midline and H-3.5 to -5 in the pons, and from P8 to PI 1, 1 mm from midline and Figure 1 . Schematic mapping of NMDA and non-NMDA agonist injection sites. Data was reconstructed from 17 cat experiments. Injection sites were located by electrical stimulation-produced atonia. Chemical stimulation at all of these sites produced changes in muscle activity. NMDA microinjection facilitated muscle tone and/or stepping-like activity, while non-NMDA agonists produced muscle suppression or atonia. The sites receiving both NMDA and non-NMDA agonist injections are indicated with arrows. 4V, forth ventricle; 5ME, mesencephalic trigeminal nucleus; 6, abducens nucleus; 7G, genu of the facial nerve; IO, inferior olivary nucleus; LC, locus coeruleus nucleus; NGC, nucleus gigantocellularis; NMC, nucleus magnocellularis; NPM, nucleus paramedianus; PG, pontine gray; PT. pyramidal tract; SO, superior olivary nucleus; T, nucleus of the trapezoid body; TB, trapezoid body. l *. 7'. NGC NPM H-7.5 to -9 in the medial medulla. We utilized sites that produced muscle tone suppression at current levels below 40 PA for our microinjection studies. NMDA injection into both pontine and NMC "inhibitory" areas, previously identified by their response to electrical stimulation (Lai and Siegel, 1988) , produced a facilitation of muscle tone and/or stepping-like activity, at all 13 sites tested (Fig. 1) . With higher levels of preinjection muscle tone (splenius muscle tone, >25 PV), NMDA injection (6.8 mM) produced tonically increased tone only (Fig. 2) , but with lower preinjection muscle tone levels, locomotion was induced by NMDA (Fig. 3) . Repeated injections at the same site produced the same effects; up to five injections of NMDA were observed to produce facilitation of muscle tone with comparable latency and duration. Microscopic analyses of injection sites did not reveal any evidence of gliosis or cell loss, indicating that the cytotoxic effects of glutamate agonists were not present at the doses employed.
The latency and duration of the NMDA-induced facilitatory (Fig. 4) , but the direction of effect was the same from threshold levels up to the maximum dosages employed; NMDA always produced increased muscle tone or locomotion, and non-NMDA agonists always produced muscle tone suppression (Figs. 3, 5) . The latency, defined as the time from the start of injection to the onset of muscle activity change, was 24 f 11.3 set (range, 12-40 set) at a 6.8 mM concentration. The facilitation of muscle tone or locomotion lasted for 3.0 f 0.67 min (range, 2.2-4.2 min) at 6.8 mM. This NMDA-induced muscle facilitation and/or locomotion was blocked by prior microinjection of 5 1 mM of o,L-2 amino-Sphosphonovaleric acid (APV; n = 7; Fig. l) , a specific NMDA antagonist. NMDA-induced muscle facilitation recovered by 3 hr after antagonist injection (Fig. 2) . Vehicle Ringer's saline microinjection produced no effect on either muscle tone or locomotion (Fig. 2) .
In contrast to the NMDA effect, non-NMDA agonists, kainate (KA), quisqualate (QA), and willardine (WL) microinjected into the same sites or into nearby inhibitory areas (Fig. l) , produced bilateral muscle tone suppression or atonia, at 42 of 44 inhibitory sites tested (Fig. 6 ). This non-NMDA-induced muscle tone suppression was also dose dependent (Fig. 4) . The latency of muscle tone suppression induced by non-NMDA injection was 20.5 f 9.7 set after 10 mM QA, 28.5 f 17.1 set after 280 PM KA, and 12.5 f 13.6 set after 100 PM WL (see Fig. 4 for N values). At the above-listed concentrations, the average duration of muscle tone suppression was 13.3 f 3.0 min after QA, 4.5 -t 1.0 min after KA, and 6.1 f 3.2 min after WL. Specific non-NMDA antagonists CNQX (10 FM) and DNQX (10 PM) attenuated or completely blocked the non-NMDA agonists' effect on muscle tone suppression (Fig. 7) . Since the blockade of the NMDA effect by the quinoxalinediones lasted > 5 hr, similar to previous reports of the long-duration effects of these compounds (Anderson et al., 1989) , only four experiments were done with CNQX and DNQX. Antagonist experiments were also done with r.,-glutamic acid diethyl ester (GDEE; 0.2 M) and gamma-o-glutamylglycine (DGG; 10 mM). Both GDEE (n = 19) and DGG (n = 8) were found to antagonize the effect of non-NMDA agonists on muscle activity, and these effects lasted < 15 min, allowing multiple tests in a single experiment.
Discussion
Microinjection of NMDA into the NMC of the medial medulla has been reported to produce locomotion (Atsuta et al., 1989; Kinjo et al., 1990) T NMDA 7mM ._---sample A.
effective in producing locomotion in both medial pons and NMC NMDA and non-NMDA receptors may be present in varying even without treadmill stimulation. The sites where NMDA is proportions on adjacent neurons. Electrophysiological studies effective are identical to those where electrical stimulation, gluhave shown that REM sleep-and motor behavior-related neutamate (Lai and Siegel, 1900) , and non-NMDA agonist mirons are intermingled in pontomedullary areas (Siegel and croinjections produce muscle tone suppression. The opposite McGinty, 1977; Siegel et al., 1979 Siegel et al., , 1983 Chandler et al., 1980) . effects of NMDA and non-NMDA agonists lead us to hypothThese neuronal subpopulations can be selectively activated as esize that muscle tone suppression and facilitation/locomotion a function of sleep-waking state. Stimulation of pontine reticular are elicited from the same sites but through different receptors.
areas produce EPSPs during wakefulness and quiet sleep and Figure 7 . DNQX blocked KA-induced muscle suppression in the NMC of the medulla. Top, Microinjection of KA produced suppression of the neck muscle activity, bilaterally. Middle, Specific non-NMDA antagonist, DNQX, produced no effect on muscle activity. Bottom, Application of KA 5 min after DNQX injection did not induce muscle suppression and actually produced a small increase in tone in LOS and LS. IPSPs during REM sleep in masseter and lumbar motoneurons (Fung et al., 1982) . Peterson and collaborators (Peterson et al., 1978 (Peterson et al., , 1979 have shown both inhibitory and excitatory reticulospinal effects from electrical stimulation of the medulla. Previous studies from our laboratory have shown that glutamate injections into the pontomedullary inhibitory areas produced muscle tone suppression only (Lai and Siegel, 1988) , presumably because the L-form of glutamate acts mainly at non-NMDA receptors (Davies et al., 1982) . The opposite effects of NMDA and non-NMDA receptors can explain the pattern of motor activity seen in REM sleep. We hypothesize that glutamate release during REM sleep produces activation of non-NMDA receptors in pontomedullary regions producing muscle atonia. Membrane depolarization resulting from non-NMDA activity in turn facilitates response to NMDA receptor activation (Nowak et al., 1984; Klein et al., 1989) in neuronal populations responsible for phasic motor excitation. This results in the characteristic pattern of twitches superimposed on a background of muscle atonia seen in REM sleep.
The REM sleep behavior disorder is a disease in which extensive motor activity occurs during REM sleep (Schenck et al., 1986) . In some cases, discrete lesions in the pontine inhibitory areas have been identified (Culebras and Moore, 1989) . However, in most cases, no overt lesion is detectable (Schenck et al., 1986) , although "soft" neurological signs are often present. We hypothesize that a diffuse degeneration within the brainstem may cause the ratio of NMDA and non-NMDA receptors, or of neurons containing these receptors to shift. We hypothesize that this process causes the NMDA response to become more prominent, resulting in increased motor activity in REM sleep.
The background excitability of the motor system has previously been shown to modulate the locomotor response to brain stimulation. Locomotion can be elicited by pontine ventral tegmentum stimulation only when the basal muscle activity is at an "optimal" intermediate level (Mori et al., 1986 ). Stimulation at "locomotor" sites is ineffective when very high or low (atonia) muscle tone levels are present at stimulation onset (Mori et al., 1986) . We have seen a similar phenomenon with NMDA injection in the present studies. NMDA agonists produce locomotion only when preinjection muscle tone is at an intermediate level. The co-localization and interaction of pontine and medullary glutamate atonia and rhythmic motor mechanisms may contribute to the coordination of postural tone and locomotion in waking.
The pontine area in which NMDA and non-NMDA agonists induced opposite effects has been shown to produce REM sleeplike activity with carbachol infusion in intact animals (George et al., 1964; van Dongen et al., 1978; Baghdoyan et al., 1984; Shiromani et al., 1986) . ACh and glutamate are co-localized in some pedunculopontine nucleus neurons (Clements and Grant, 1990) . We hypothesize that neurons containing glutamate, ACh, or both of these transmitters project to the ACh-Glu receptive area that we have explored in the medial pons. The co-release of these transmitters may be required for the full expression of REM sleep phenomena.
